Protara Therapeutics (TARA) - Long-Term Debt to Capital

Corporate emblem and logo of Protara Therapeutics (TARA)

This chart of the current share price of Protara Therapeutics (TARA), supported by Jesse Shem, demonstrates confident capital control and clinic development, where the metric reaches 0.01. Protara Therapeutics is accelerating drug releases through partnerships with scientific centers. The business relies on creating targeted medicines for patients with rare tumors, counting on future payments from government insurance funds.

Protara - TARA Long-Term Debt to Capital (period 07/04/2022 - 10/29/2026)

Analytical breakdowns for Protara Therapeutics

- stock value and consensus price forecast:
Stock Quotes Protara Therapeutics Inc|TARA - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Protara Therapeutics, Inc.|TARA - Total Company Value
- company book value details:
Equity per Share Protara Therapeutics|TARA - Book Capitalization|Market Cap to Net Assets Ratio protaratx.com|TARA - Company Total Assets
- company liabilities and liquidity data:
Debt to Capital Protara Therapeutics|TARA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital protaratx.com|TARA - Company Total Debt|Debt to Net Assets Ratio Protara Therapeutics, Inc.|TARA - Company Long-Term Debts|Company Current Liabilities Protara Therapeutics|Quick Ratio protaratx.com
- financial results and valuation multiples details:
TARA - Company Net Income
General company analysis:Protara Therapeutics Inc - TARA
Original product of protaratx.com

This indicator determines the proportion of long-term liabilities relative to equity, allowing for an assessment of financial autonomy and the risks associated with servicing loans with a maturity horizon of over one year. By analyzing the ratio of long-term debt to equity, an investor can understand the extent to which Protara Therapeutics (TARA) relies on external borrowings to finance its capital-intensive R&D platforms in precision oncology and cell therapy.

Key competitors

Long-Term Debt to Equity Ratio BeiGene Ltd. (ONC)|Long-Term Debt to Capital HALO|Long-Term Debt to Capital Revolution Medicines Corp (RVMD)|Long-Term Debt to Equity Ascentage Pharma Group AAPG|CGON: Long-Term Debt to Capital Ratio|UroGen Pharma - Long-Term Debt to Capital|Bicara Therapeutics Inc (BCAX) - Long-Term Debt to Equity Ratio|PSNL: Long-Term Debt to Capital|Long-Term Liabilities to Capital Erasca Oncology (ERAS)|Long-Term Debt to Equity Delcath Systems, Inc.|YMAB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio AURA (Aura Biosciences)|CADL (candeltx.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ARAY (Accuray Inc.)|SLS - Long-Term Debt to Equity Ratio|ACTU: Long-Term Debt to Equity Ratio|CTOR - Long-Term Debt to Capital|tuhurabio.com (HURA) - Long-Term Debt to Equity|Fate Therapeutics Inc - Long-Term Debt to Capital Coefficient|WHWK (Aadi Bioscience, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital TScan TCRX|Long-Term Debt to Equity Champions Oncology (CSBR)|XBIT: Long-Term Liabilities to Equity|Long-Term Debt to Equity CEL-SCI CVM|Long-Term Debt to Capital Coefficient OSTX|RADX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Artiva Biotherapeutics, Inc.|ANL (adlainortye.com) - Long-Term Debt to Equity Ratio|VERU: Long-Term Loans to Capital Ratio|TPST (Tempest Therapeutics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital Xilio|Long-Term Debt to Equity Renovaro Inc. (RENB)|MURA (muraloncology.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital KAPA (Kairos Pharma)|Long-Term Debt to Capital OnKure Therapeutics, Inc. OKUR|GDTC: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient CRIS (Curis, Inc.)|APLM (apollomicsinc.com) - Long-Term Debt to Equity Ratio|THAR: Long-Term Loans to Capital Ratio|ADVB (Advanced Biomed Inc.) - Long-Term Debt to Capital|GNPX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital CLDI|SBFM - Long-Term Liabilities to Capital|Long-Term Debt to Equity Xenetic Biosciences, Inc. XBIO|Long-Term Debt to Capital Coefficient SLRX|Purple Biotech - Long-Term Debt to Capital|AONC - Long-Term Debt to Capital|BeiGene (BGNE) - Long-Term Debt to Equity|Long-Term Liabilities to Equity CKPT (Checkpoint Therapeutics Inc.)|ELEV (Elevation Oncology, Inc.) - Long-Term Debt to Capital|Long-Term Liabilities to Capital iCAD Corp ICAD|Long-Term Debt to Equity Ratio IKNA (Ikena Oncology, Inc.)|Long-Term Debt to Capital notablelabs.com (NTBL)|Viracta Therapeutics, Inc. - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio MOR (MorphoSys Inc)|NAYA Bio - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Ascentage AAPGV